Resumen:
Objectives: To compare the activity of tedizolid (formally known as torezolid and TR-700) with that of 15 agents
against a collection of linezolid-resistant staphylococci (164 coagulase-negative staphylococci and
5 Staphylococcus aureus).
Methods: Antimicrobial susceptibility tests were performed using the broth microdilution method following the
recommendations of the CLSI.
Results: All isolates were susceptible to vancomycin and tigecycline. Based on the MIC90 values, the potency of
tedizolid against coagulase-negative staphylococci was .16-fold greater than that of linezolid. Tedizolid
retained activity against most of the linezolid-resistant staphylococci tested, including multidrug-resistant isolates
with elevated linezolid MICs (32 to .128 mg/L). Of the isolates, 79.2% and 31.4% were inhibited by
tedizolid at ≤4 mg/L and ≤2 mg/L, respectively.
Conclusions: The results of this study confirm the activity of tedizolid against linezolid-resistant staphylococci. This
new oxazolidinone could have an important role as a potential therapeutic agent against multidrug-resistant
staphylococci.